iTeos Therapeutics announced that the GALAXIES Lung-201 Phase 2 trial, assessing the combination of belrestotug and dostarlimab for lung cancer, did not meet the criteria for clinically meaningful ...

If this company only had belrestotug left, then I would be inclined to move this to a "Sell" rating. However, it still has two other drugs left in its pipeline, which are EOS-984 and EOS-215.

All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial is ending. GSK is communicating with investigators, ...

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate ...

The two companies were working together assessing the Belrestotug + Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.

GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class.

Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the ...

GALAXIES Lung-201 trial showed ORR benefit but failed to meet PFS criteria for belrestotug combo vs. monotherapy. iTeos holds $624.3 million in cash as of March 31, 2025, with a projected runway ...

WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate ...

WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...